114 related articles for article (PubMed ID: 20806183)
21. Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study.
Vezzosi D; Walter T; Laplanche A; Raoul JL; Dromain C; Ruszniewski P; d'Herbomez M; Guigay J; Mitry E; Cadiot G; Leboulleux S; Lombard-Bohas C; Borson-Chazot F; Ducreux M; Baudin E
Int J Biol Markers; 2011; 26(2):94-101. PubMed ID: 21574156
[TBL] [Abstract][Full Text] [Related]
22. Octreotide suppression test in diagnosing and predicting the outcome of therapy in patients with neuroendocrine tumors. Preliminary report.
Kos-Kudła B; Zemczak A; Foltyn W; Marek B; Strzelczyk J; Telega A; Zajecki W; Legaszewski T; Jurecka-Lubieniecka B
Endokrynol Pol; 2007; 58(2):123-9. PubMed ID: 17578828
[TBL] [Abstract][Full Text] [Related]
23. Measurements of chromogranin B can serve as a complement to chromogranin A.
Stridsberg M; Eriksson B; Fellström B; Kristiansson G; Tiensuu Janson E
Regul Pept; 2007 Mar; 139(1-3):80-3. PubMed ID: 17116339
[TBL] [Abstract][Full Text] [Related]
24. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids.
Peracchi M; Gebbia C; Basilisco G; Quatrini M; Tarantino C; Vescarelli C; Massironi S; Conte D
Eur J Endocrinol; 2005 Mar; 152(3):443-8. PubMed ID: 15757862
[TBL] [Abstract][Full Text] [Related]
25. Cross-correlation of serum chromogranin A, %-F-PSA and bone scans in prostate cancer diagnosis.
Ahel MZ; Kovacic K; Tarle M
Anticancer Res; 2001; 21(2B):1363-6. PubMed ID: 11396214
[TBL] [Abstract][Full Text] [Related]
26. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
Zissimopoulos A; Bantis A; Sountoulides P; Giannakopoulos S; Kalaitzis C; Agelonidou E; Touloupidis S
Hell J Nucl Med; 2009; 12(3):234-7. PubMed ID: 19936334
[TBL] [Abstract][Full Text] [Related]
27. Implications of circulating chromogranin A in prostate cancer.
Hirano D; Minei S; Sugimoto S; Yamaguchi K; Yoshikawa T; Hachiya T; Kawata N; Yoshida T; Takahashi S
Scand J Urol Nephrol; 2007; 41(4):297-301. PubMed ID: 17763220
[TBL] [Abstract][Full Text] [Related]
28. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
29. Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma.
Sciarra A; Di Silverio F; Autran AM; Salciccia S; Gentilucci A; Alfarone A; Gentile V
Urol Int; 2009; 82(2):147-51. PubMed ID: 19321999
[TBL] [Abstract][Full Text] [Related]
30. Chromogranin A and the endothelial barrier function.
Corti A; Ferrero E
Curr Med Chem; 2012; 19(24):4051-8. PubMed ID: 22834794
[TBL] [Abstract][Full Text] [Related]
31. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
[TBL] [Abstract][Full Text] [Related]
32. Chromogranin A in gastrinomas: Promises and pitfalls.
Rehfeld JF
Clin Chim Acta; 2015 Jun; 446():15-20. PubMed ID: 25861845
[TBL] [Abstract][Full Text] [Related]
33. Chromogranin A--serum marker for prostate cancer.
Khan MO; Ather MH
J Pak Med Assoc; 2011 Jan; 61(1):108-11. PubMed ID: 22368921
[TBL] [Abstract][Full Text] [Related]
34. Automated two-site immunofluorescent assay for the measurement of serum chromogranin A.
Popovici T; Moreira B; Schlageter MH; Bories PN
Clin Biochem; 2014 Jan; 47(1-2):87-91. PubMed ID: 24201067
[TBL] [Abstract][Full Text] [Related]
35. Chromogranin A: any relevance in neuroendocrine tumors?
Kidd M; Bodei L; Modlin IM
Curr Opin Endocrinol Diabetes Obes; 2016 Feb; 23(1):28-37. PubMed ID: 26627724
[TBL] [Abstract][Full Text] [Related]
36. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
[TBL] [Abstract][Full Text] [Related]
37. Effect of proton-pump inhibitor therapy on serum chromogranin a level.
Pregun I; Herszényi L; Juhász M; Miheller P; Hritz I; Patócs A; Rácz K; Tulassay Z
Digestion; 2011; 84(1):22-8. PubMed ID: 21304238
[TBL] [Abstract][Full Text] [Related]
38. Comparative effect of finasteride and dutasteride on chromogranin A levels.
Sciarra A; Salciccia S; Nesi G; Cattarino S; Alfarone A; Gentilucci A; Gentile V
Anticancer Res; 2010 Nov; 30(11):4737-42. PubMed ID: 21115933
[TBL] [Abstract][Full Text] [Related]
39. Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasia.
Zitella A; Berruti A; Destefanis P; Mengozzi G; Torta M; Ceruti C; Casetta G; Mosca A; Greco A; Rolle L; Aimo G; Aroasio E; Tizzani A; Dogliotti L; Fontana D;
Clin Chim Acta; 2007 Feb; 377(1-2):103-7. PubMed ID: 17034778
[TBL] [Abstract][Full Text] [Related]
40. Chromogranin A assay in clinical practice.
d'Herbomez M; Do Cao C; Vezzosi D; Borzon-Chasot F; Baudin E;
Ann Endocrinol (Paris); 2010 Sep; 71(4):274-80. PubMed ID: 20538257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]